-online.com antibodies

Datasheet for ABIN2180547 CD137 Protein (AA 24-186) (Fc Tag)

3 Images



Overview

Quantity:	100 µg
Quantity.	
Target:	CD137 (TNFRSF9)
Protein Characteristics:	AA 24-186
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	Recombinant
Biological Activity:	Active
Purification tag / Conjugate:	This CD137 protein is labelled with Fc Tag.


Product Details


Sequence:	AA 24-186
Characteristics:	This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 43.3 kDa. The protein migrates as 50-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity:	>95 % as determined by SDS-PAGE.
Sterility:	0.22 µm filtered
Endotoxin Level:	Less than 1.0 EU per μg by the LAL method.
Target Details	
Target:	CD137 (TNFRSF9)


Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 1/3 | Product datasheet for ABIN2180547 | 09/11/2023 | Copyright antibodies-online. All rights reserved.

Target Details	
Alternative Name:	4-1BB (TNFRSF9 Products)
Background:	 4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.
Molecular Weight:	43.4 kDa
NCBI Accession:	NP_001552
Pathways:	Cancer Immune Checkpoints
Application Details	
Restrictions: Handling	For Research Use only
Format:	Lyophilized
Buffer:	Tris with Glycine, Arginine and NaCl, pH 7.5
Handling Advice:	Please avoid repeated freeze-thaw cycles.
Storage:	-20 °C
Storage Comment:	No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C-8 °C), After reconstitution under sterile conditions for 1 month (4 °C-8 °C) or 3 months (-20 °C to -70 °C).

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 2/3 | Product datasheet for ABIN2180547 | 09/11/2023 | Copyright antibodies-online. All rights reserved.







ELISA

Image 1. Immobilized Human 4-1BB, Fc Tag (ABIN2180548,ABIN2180547) at 1 μ g/mL (100 μ L/well) can bind A 4-1BB MAb, Human IgG4 with a linear range of 0.2-3 ng/mL (Routinely tested).

SDS-PAGE

Image 2. Human 4-1BB, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

ELISA

Image 3. Immobilized Human 4-1BB, Fc Tag (ABIN2180548,ABIN2180547) at 0.1 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB Ligand, Fc,Avitag (ABIN5954977,ABIN6253642) with a linear range of 0.4-6 ng/mL (QC tested).

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 3/3 | Product datasheet for ABIN2180547 | 09/11/2023 | Copyright antibodies-online. All rights reserved.